Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.

You may also be interested in...



Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree

Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting

Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree

Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting

Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree

FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS067112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel